Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 145040
Corporate User License Price USD 6000
Corporate User License Price INR 435120
Site License Price USD 4000
Site License Price INR 290080
Request a Quote

Report Title

Hepatitis C-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hepatitis C-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hepatitis C-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hepatitis C-Pipeline Review, H1 2017



Executive Summary

Hepatitis C-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C-Pipeline Review, H1 2017, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 23, 15, 1, 52, 45 and 4 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 3, 1, 9 and 23 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 6

Hepatitis C-Overview 7

Hepatitis C-Therapeutics Development 8

Hepatitis C-Therapeutics Assessment 29

Hepatitis C-Companies Involved in Therapeutics Development 39

Hepatitis C-Drug Profiles 74

Hepatitis C-Dormant Projects 388

Hepatitis C-Discontinued Products 405

Hepatitis C-Product Development Milestones 410

Appendix 424

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Hepatitis C, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Hepatitis C, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hepatitis C-Pipeline by 3-V Biosciences Inc, H1 2017

Hepatitis C-Pipeline by AbbVie Inc, H1 2017

Hepatitis C-Pipeline by AIMM Therapeutics BV, H1 2017

Hepatitis C-Pipeline by Akshaya Bio Inc, H1 2017

Hepatitis C-Pipeline by Amarillo Biosciences Inc, H1 2017

Hepatitis C-Pipeline by Amarna Therapeutics BV, H1 2017

Hepatitis C-Pipeline by ARA Healthcare Pvt Ltd, H1 2017

Hepatitis C-Pipeline by Aviragen Therapeutics Inc, H1 2017

Hepatitis C-Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017

Hepatitis C-Pipeline by Beta Pharma Inc, H1 2017

Hepatitis C-Pipeline by Biocad, H1 2017

Hepatitis C-Pipeline by Biotest Pharmaceuticals Corp, H1 2017

Hepatitis C-Pipeline by Biotron Ltd, H1 2017

Hepatitis C-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Hepatitis C-Pipeline by Bolder Biotechnology Inc, H1 2017

Hepatitis C-Pipeline by Bristol-Myers Squibb Company, H1 2017

Hepatitis C-Pipeline by Cocrystal Pharma Inc, H1 2017

Hepatitis C-Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Hepatitis C-Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Hepatitis C-Pipeline by DEKK-TEC Inc, H1 2017

Hepatitis C-Pipeline by Delpor Inc, H1 2017

Hepatitis C-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hepatitis C-Pipeline by Formune SL, H1 2017

Hepatitis C-Pipeline by Genecode AS, H1 2017

Hepatitis C-Pipeline by GeneCure LLC, H1 2017

Hepatitis C-Pipeline by Gilead Sciences Inc, H1 2017

Hepatitis C-Pipeline by GinkgoPharma Co Ltd, H1 2017

Hepatitis C-Pipeline by GlaxoSmithKline Plc, H1 2017

Hepatitis C-Pipeline by HanAll Biopharma Co Ltd, H1 2017

Hepatitis C-Pipeline by ImmunoBiology Ltd, H1 2017

Hepatitis C-Pipeline by ImmunoClin Corp, H1 2017

Hepatitis C-Pipeline by Immunotope Inc, H1 2017

Hepatitis C-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Hepatitis C-Pipeline by Integrated BioTherapeutics Inc, H1 2017

Hepatitis C-Pipeline by JN-International Medical Corp, H1 2017

Hepatitis C-Pipeline by Johnson & Johnson, H1 2017

Hepatitis C-Pipeline by Karyopharm Therapeutics Inc, H1 2017

Hepatitis C-Pipeline by Kineta Inc, H1 2017

Hepatitis C-Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Hepatitis C-Pipeline by Medivir AB, H1 2017

Hepatitis C-Pipeline by Merck & Co Inc, H1 2017

Hepatitis C-Pipeline by Microbio Co Ltd, H1 2017

Hepatitis C-Pipeline by Microbiotix Inc, H1 2017

Hepatitis C-Pipeline by MultiCell Technologies Inc, H1 2017

Hepatitis C-Pipeline by NeuroVive Pharmaceutical AB, H1 2017

Hepatitis C-Pipeline by Novalex Therapeutics Inc, H1 2017

Hepatitis C-Pipeline by Novartis AG, H1 2017

Hepatitis C-Pipeline by NovaTarg Therapeutics Inc, H1 2017

Hepatitis C-Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Hepatitis C-Pipeline by Pfenex Inc, H1 2017

Hepatitis C-Pipeline by Pfizer Inc, H1 2017

Hepatitis C-Pipeline by PharmaEssentia Corp, H1 2017

Hepatitis C-Pipeline by Presidio Pharmaceuticals Inc, H1 2017

Hepatitis C-Pipeline by Profectus BioSciences Inc, H1 2017

Hepatitis C-Pipeline by Replicor Inc, H1 2017

Hepatitis C-Pipeline by Rodos BioTarget GmbH, H1 2017

Hepatitis C-Pipeline by Solon Eiendom ASA, H1 2017

Hepatitis C-Pipeline by SomaGenics Inc, H1 2017

Hepatitis C-Pipeline by Sorrento Therapeutics Inc, H1 2017

Hepatitis C-Pipeline by Sudershan Biotech Ltd, H1 2017

Hepatitis C-Pipeline by TaiGen Biotechnology Co Ltd, H1 2017

Hepatitis C-Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017

Hepatitis C-Pipeline by Therapure Biopharma Inc, H1 2017

Hepatitis C-Pipeline by Theravectys SA, H1 2017

Hepatitis C-Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017

Hepatitis C-Pipeline by Vakzine Projekt Management GmbH, H1 2017

Hepatitis C-Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Hepatitis C-Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017

Hepatitis C-Pipeline by Zylacta Corp, H1 2017

Hepatitis C-Dormant Projects, H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..1), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..2), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..3), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..4), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..5), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..6), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..7), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..8), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..9), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..10), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..11), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..12), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..13), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..14), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..15), H1 2017

Hepatitis C-Dormant Projects, H1 2017 (Contd..16), H1 2017

Hepatitis C-Discontinued Products, H1 2017

Hepatitis C-Discontinued Products, H1 2017 (Contd..1), H1 2017

Hepatitis C-Discontinued Products, H1 2017 (Contd..2), H1 2017

Hepatitis C-Discontinued Products, H1 2017 (Contd..3), H1 2017

Hepatitis C-Discontinued Products, H1 2017 (Contd..4), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

3-V Biosciences Inc, AbbVie Inc, AIMM Therapeutics BV, Akshaya Bio Inc, Amarillo Biosciences Inc, Amarna Therapeutics BV, ARA Healthcare Pvt Ltd, Aviragen Therapeutics Inc, Beijing Kawin Technology Share-Holding Co Ltd, Beta Pharma Inc, Biocad, Biotest Pharmaceuticals Corp, Biotron Ltd, Boehringer Ingelheim GmbH, Bolder Biotechnology Inc, Bristol-Myers Squibb Company, Cocrystal Pharma Inc, Conatus Pharmaceuticals Inc, ContraVir Pharmaceuticals Inc, DEKK-TEC Inc, Delpor Inc, F. Hoffmann-La Roche Ltd, Formune SL, Genecode AS, GeneCure LLC, Gilead Sciences Inc, GinkgoPharma Co Ltd, GlaxoSmithKline Plc, HanAll Biopharma Co Ltd, ImmunoBiology Ltd, ImmunoClin Corp, Immunotope Inc, Inovio Pharmaceuticals Inc, Integrated BioTherapeutics Inc, JN-International Medical Corp, Johnson & Johnson, Karyopharm Therapeutics Inc, Kineta Inc, Ligand Pharmaceuticals Inc, Medivir AB, Merck & Co Inc, Microbio Co Ltd, Microbiotix Inc, MultiCell Technologies Inc, NeuroVive Pharmaceutical AB, Novalex Therapeutics Inc, Novartis AG, NovaTarg Therapeutics Inc, Ono Pharmaceutical Co Ltd, Pfenex Inc, Pfizer Inc, PharmaEssentia Corp, Presidio Pharmaceuticals Inc, Profectus BioSciences Inc, Replicor Inc, Rodos BioTarget GmbH, Solon Eiendom ASA, SomaGenics Inc, Sorrento Therapeutics Inc, Sudershan Biotech Ltd, TaiGen Biotechnology Co Ltd, TaiwanJ Pharmaceuticals Co Ltd, Therapure Biopharma Inc, Theravectys SA, THEVAX Genetics Vaccine USA Inc, Vakzine Projekt Management GmbH, Vertex Pharmaceuticals Inc, WhanIn Pharmaceutical Co Ltd, Zylacta Corp


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand